Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AttraX Putty vs. Autograft in XLIF
NCT02250248Completed
- Sponsor
- NuVasive
- Start
- Dec 2014
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by NuVasive. Primary endpoint: Radiographically Apparent Fusion Rate at 24 months. Started Dec 2014; status: completed.
Beyond the preview
Go deeper on NCT02250248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250248.